All News

RheumNow Podcast square

Mentshlichkeit* (8.7.2026)

Jack Cush, MD

Dr. Jack Cush reviews the news and recent journal reports on RheumNow.com.

Read Article
Eosinophil

Rethinking Treatment of EGPA

Jack Cush, MD

Eosinophilic granulomatosis with polyangiitis (EGPA) has long been managed by extrapolating results from microscopic polyangiitis and granulomatosis with polyangiitis clinical trials. But new insights into EGPA's has lead to advances in therapy and new treatment paradigms.

Read Article
FDA.Safety.jpg

New Avacopan Analysis Sent to FDA

MedPage Today

After data manipulation allegations, the FDA has been calling for the vasculitis drug to be pulled from the market since January.

Read Article
RheumNow Podcast square

Gout Cavalcade (7.10.2026)

Jack Cush, MD

Dr. Jack Cush reviews the news, journal articles and regulatory decisions from the past week. July is Gout: More than Flares month.

Read Article
NEJM.Magnify

NEJM Retracts Pivotal ADVOCATE Trial of FDA-Approved Avacopan

MedPage Today

The New England Journal of Medicine (NEJM) retracted the pivotal study supporting FDA's approval of avacopan (Tavneos) for severe forms of anti-neutrophil cytoplasmic

Read Article
Giant-Cell_Vasculitis.jpg

EULAR26: Vasculitis updates: Glucorticoid use in AAV and GCA

EurekAlert!

EULAR recommends a combination of glucocorticoids with either rituximab or cyclophosphamide for remission induction in life-threatening or organ-threatening AAV, followed by gradual tapering of glucocorticoids.

Read Article
Eosinophil

ICYMI: EGPA Review

Jack Cush, MD

A current review of eosinophilic granulomatosis with polyangiitis (EGPA) provides current recommendations on diagnosis and management.

Read Article
Blood labs

2-Gene Blood Test for Kawasaki Disease in Febrile Children

Jack Cush, MD

JAMA Network Open has publshed that a simple 2-gene blood test may aid the earlier diagnosis of Kawasaki disease in children with febrile illnesses. 

Read Article
RheumNow Podcast square

Do You Zoster Vaccinate? (6.19.2026)

Jack Cush, MD

Dr. Jack Cush reviews the news, journal reports and best ways to review EULAR 2026.

Read Article
recommendations on computer screen

EULAR 2026 Recommendations on PMR, GCA, and Takayasu Arteritis

Jack Cush, MD

On the final day of EULAR 2026, Mukhtyar et al (on behalf of a large international task force) presented the updated EULAR recommendations for management of polymyalgia rheumatica (PMR), giant cell arteritis (GCA), and Takayasu arteritis (TAK). There were 5 overarching principles and 12 recommendations.

Read Article
A Case of Sweet Syndrome https://t.co/M4ERsHnnH7 https://t.co/88bqEemJG8

Links:

Dr. John Cush RheumNow ( View Tweet)
CDC warns of an association betw severe CNS arboviral disease, w/ neurologic sequelae in pts receiving anti-CD20 mAbs (rituximab, ocrelizumab, ofatumumab, obinutuzumab, etc). West Nile virus was the most common arbovirus, but there are others; mortality up to 40%. Most arbovirus https://t.co/7eMoNgWbB4
Dr. John Cush RheumNow ( View Tweet)
What's New in Lyme Disease JAMA has published an overview of new considerations on Lyme disease, focusing on Diagnostics, Vaccines, and Prevention. https://t.co/jG09wc6gI8 https://t.co/rQBW6RIz5U

Links:

Dr. John Cush RheumNow ( View Tweet)
Rethinking Treatment of EGPA Like MPA & GPA, the goals of EGPA are controlling initial organ damage and preventing relapse. But EGPA has the added challenge of chronic upper and lower respiratory tract involvement, allergic type 2 inflammations and risk of glucocorticoid https://t.co/KIVpyhsghg
Dr. John Cush RheumNow ( View Tweet)
New Avacopan Analysis Sent to FDA After data manipulation allegations, the FDA has been calling for the vasculitis drug to be pulled from the market since January. Amgen has submitted a third-party review of avacopan's (Tavneos) pivotal trial data and other analyses to the FDA https://t.co/zBg4pFBfSP
Dr. John Cush RheumNow ( View Tweet)
New Avacopan Analysis Sent to FDA After data manipulation allegations, the FDA has been calling for the vasculitis drug to be pulled from the market since January. Amgen has submitted a third-party review of avacopan's (Tavneos) pivotal trial data and other analyses to the FDA https://t.co/TdLWRMPvnR
Dr. John Cush RheumNow ( View Tweet)
NEJM Retracts Pivotal ADVOCATE Trial of FDA-Approved Avacopan The New England Journal of Medicine (NEJM) retracted the pivotal study supporting FDA's approval of avacopan (Tavneos) for severe forms of anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis. https://t.co/GOVyk5poNq
Dr. John Cush RheumNow ( View Tweet)
DERM on RheumNow (June 2026) The Derm on RheumNow podcast is a collection of Citations and Content curated for dermatologists – addressing Psoriasis, PsA, CLE, vasculitis, HS, other CTD skin disorders. dermatology drugs, biologics, JAKs - their use, efficacy and side effects. https://t.co/vy4BAx8Lnq
Dr. John Cush RheumNow ( View Tweet)
EULAR 2026 Recommendations on PMR, GCA, and Takayasu Arteritis On the final day of EULAR, Mukhtyar et al (on behalf of a large international task force) presented the updated EULAR recommendations for management of PMR, GCA, and TAK. There were 5 overarching principles and 12 https://t.co/kpykylEbsr
Dr. John Cush RheumNow ( View Tweet)
Vasculitis Updates: Glucocorticoid use in AAV and GCA Vasculitis Updates: Glucocorticoids are the cornerstone of initial therapy for AAV and GCA—quickly reducing inflammation and preserving organs. EULAR has issued recommendations on glucocorticoid use in ANCA‑associated and https://t.co/hIOKyXDxyb
Dr. John Cush RheumNow ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×